Serum survey for antibodies to coronavirus, herpesvirus, calicivirus, and parvovirus in domestics cats from Rio Grande do Sul, Brazil

Frequent Infection of Cats With SARS-CoV-2 Irrespective of Pre-Existing Enzootic Coronavirus Immunity, Brazil 2020

Carnivores such as cats and minks are highly susceptible to SARS-CoV-2. Brazil is a global COVID-19 hot spot and several cases of human-to-cat transmission have been documented. We investigated the spread of SARS-CoV-2 by testing 547 domestic cats sampled between July-November 2020 from seven states in southern, southeastern, and northeastern Brazil. Moreover, we investigated whether immune responses elicited by enzootic coronaviruses affect SARS-CoV-2 infection in cats. We found infection with significantly higher neutralizing antibody titers against the Gamma variant of concern, endemic in Brazil during 2020, than against an early SARS-CoV-2 B.1 isolate (p<0.0001), validating the use of Gamma for further testing. The overall SARS-CoV-2 seroprevalence in Brazilian cats during late 2020 validated by plaque reduction neutralization test (PRNT₉₀) was 7.3% (95% CI, 5.3-9.8). There was no significant difference in SARS-CoV-2 seroprevalence in cats between Brazilian states, suggesting homogeneous infection levels ranging from 4.6% (95% CI, 2.2-8.4) to 11.4% (95% CI, 6.7-17.4; p=0.4438). Seroprevalence of the prototypic cat coronavirus Feline coronavirus (FCoV) in a PRNT₉₀ was high at 33.3% (95% CI, 24.9-42.5) and seroprevalence of Bovine coronavirus (BCoV) was low at 1.7% (95% CI, 0.2-5.9) in a PRNT₉₀. Neutralizing antibody titers were significantly lower for FCoV than for SARS-CoV-2 (p=0.0001), consistent with relatively more recent infection of cats with SARS-CoV-2. Neither the magnitude of SARS-CoV-2 antibody titers (p=0.6390), nor SARS-CoV-2 infection status were affected by FCoV serostatus (p=0.8863). Our data suggest that pre-existing immunity against enzootic coronaviruses neither prevents, nor enhances SARS-CoV-2 infection in cats. High SARS-CoV-2 seroprevalence already during the first year of the pandemic substantiates frequent infection of domestic cats and raises concerns on potential SARS-CoV-2 mutations escaping human immunity upon spillback.

Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group

The World Small Animal Veterinary Association Vaccination Guidelines Group has produced global guidelines for small companion animal practitioners on best practice in canine and feline vaccination. Recognising that there are unique aspects of veterinary practice in certain geographical regions of the world, the Vaccination Guidelines Group undertook a regional project in Latin America between 2016 and 2019, culminating in the present document. The Vaccination Guidelines Group gathered scientific and demographic data during visits to Argentina, Brazil and Mexico, by discussion with national key opinion leaders, visiting veterinary practices and review of the scientific literature. A questionnaire survey was completed by 1390 veterinarians in five Latin American countries and the Vaccination Guidelines Group delivered continuing education at seven events attended by over 3500 veterinarians.

The Vaccination Guidelines Group recognised numerous challenges in Latin America, for example: (1) lack of national oversight of the veterinary profession, (2) extraordinary growth in private veterinary schools of undetermined quality, (3) socioeconomic constraints on client engagement with preventive health care, (4) high regional prevalence of some key infectious diseases (e.g. feline leukaemia virus infection, canine visceral leishmaniosis), (5) almost complete lack of minimal antigen vaccine products as available in other markets, (6) relative lack of vaccine products with extended duration of immunity as available in other markets, (7) availability of vaccine products withdrawn from other markets (e.g. Giardia vaccine) or unique to Latin America (e.g. some Leishmania vaccines), (8) accessibility of vaccines directly by pet owners or breeders such that vaccination is not delivered under veterinary supervision, (9) limited availability of continuing education in veterinary vaccinology and lack of compulsion for continuing professional development and (10) limited peer‐reviewed published scientific data on small companion animal infectious diseases (with the exception of leishmaniosis) and lack of support for such academic research.

In this document, the Vaccination Guidelines Group summarises the findings of this project and assesses in evidence‐based fashion the scientific literature pertaining to companion animal vaccine‐preventable diseases in Latin America. The Vaccination Guidelines Group makes some recommendations on undergraduate and postgraduate education and academic research. Recognising that current product availability in Latin America does not permit veterinarians in these countries to vaccinate according to the global World Small Animal Veterinary Association guidelines, the Vaccination Guidelines Group makes a series of “pragmatic” recommendations as to what might be currently achievable, and a series of “aspirational” recommendations as to what might be desirable for the future. The concept of “vaccine husbandry” is addressed via some simple guidelines for the management of vaccine products in the practice. Finally, the Vaccination Guidelines Group emphasises the global trend towards delivery of vaccination as one part of an “annual health check” or “health care plan” that reviews holistically the preventive health care needs of the individual pet animal. Latin American practitioners should transition towards these important new practices that are now well embedded in more developed veterinary markets.

The document also includes 70 frequently asked questions and their answers; these were posed to the Vaccination Guidelines Group during our continuing education events and small group discussions and should address many of the issues surrounding delivery of vaccination in the Latin American countries. Spanish and Portuguese translations of this document will be made freely available from the on‐line resource pages of the Vaccination Guidelines Group.

Prevalence of viral infections in Norwegian cats with and without feline lower urinary tract disease

The prevalence of various viral infections was examined in primary accession cases of feline lower urinary tract disease (FLUTD) and healthy control cats in Norway. Urine samples from 102 cats with clinical signs of FLUTD and 73 healthy control cats were tested for the presence of feline calicivirus (FCV), feline coronavirus (FCoV) and feline herpesvirus-1 (FHV-1) by polymerase chain reaction. All urinary samples were negative for FCV and FCoV. One (1%) of the FLUTD cats was found to be positive for FHV-1. The results did not indicate an association between the viral infections examined and signs of FLUTD in the study sample.

Nested case-control study of feline calicivirus viruria, oral carriage, and serum neutralizing antibodies in cats with idiopathic cystitis

BACKGROUND

The epidemiology of feline calicivirus (FCV) infection in cats with idiopathic cystitis (FIC) has not been investigated by contemporary molecular biologic methods.

OBJECTIVES

To determine the prevalence of and evaluate risk factors for FCV viruria, oral carriage, and virus neutralizing (VN) antibodies in cats with and without FIC.

ANIMALS

Cats with nonobstructive FIC (n = 47), obstructive FIC (n = 22), and FCV upper respiratory tract infection (URI; n = 25), and healthy client-owned (n = 18) and colony-housed (n = 24) cats.

METHODS

Oropharyngeal secretions and urine were evaluated with a FCV p30 gene-based real-time reverse-transcriptase polymerase chain reaction (RT-PCR) assay. Serum VN antibody titers were determined by a modified microtiter assay. Associations of risk factors with log-transformed antibody titers were determined by multivariable generalized linear regression.

RESULTS

FCV viruria was detected in 4 (6%) and 3 (12%) cats with FIC and URI, respectively. In 3 FIC cats, viruria was unassociated with detectable oral virus carriage. Oral FCV carriage was detected in 7 (10%) FIC cats. Median antibody titers were significantly higher in cats with obstructive FIC (1 :256), nonobstructive FIC (1:128), and URI (1:512) compared with healthy client-owned (1:16) and colony-housed (1:4) cats (P < .001). Other than disease, multivariate analysis did not identify any other explanatory variables for increased titers in cats with FIC or URI.

CONCLUSIONS AND CLINICAL IMPORTANCE

FCV viruria was detected in cats with FIC and URI, however, its etiologic significance is uncertain. Serologic results suggest increased FCV exposure in FIC cats compared with controls. Further investigations are needed to clarify the potential role of FCV in FIC.